Gmp Cytokines Market Scope And Analysis

  • Report Code : TIPRE00008212
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

GMP Cytokines Market Scope, Growth, Size and Share by 2031

Buy Now


GMP Cytokines Market Report Scope

Report Attribute Details
Market size in 2023 US$ 128.7 Million
Market Size by 2031 US$ 350.2 Million
Global CAGR (2023 - 2031) 9.7%
Historical Data 2021-2022
Forecast period 2023-2031
Segments Covered By Type
  • TNF
  • Interleukins
  • Growth Factors
By Application
  • Cell and Gene Therapy
  • Tissue Engineered Products
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Miltenyi Biotec
  • Sino Biological Inc
  • ABCAM
  • PeproTech Inc
  • Akron Biotech
  • CellGenix GmbH
  • BIO TECHNE CORPORATION
  • CREATIVE BIOARRAY
  • Proteintech Group Inc
  • REPROCELL Inc
  • GMP Cytokines Market News and Recent Developments

    The GMP cytokines market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for innovations, business expansion, and strategies:

    • In March 2024, Synthekine Inc. an engineered cytokine therapeutics company announced releasing of Phase 1a/1b clinical trials of α/β biased IL-2 partial agonist, STK-012. (Source: Synthekine, Press Release)
    • In March 2022, Xenco, a clinical-stage biopharmaceutical company announced developing engineered antibodies and cytokines to treat cancer and autoimmune diseases and are preclinical data presented from XmAb Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022.
    • In July 2022, Sandoz announced US Food and Drug Administration (USFDA) for its Supplemental Biologics Licence Application (sBLA) for a high concentration formulation of 100mg/ml (HCF) of its biosimilar "Hyrimoz" (Adalimumab-adaz). The application includes the indications of the reference medicines Humira (adalimumab) not protected by orphan exclusivity, including the rheumatoid arthritis, juvenile idiopathic arthritis, psoriasis arthritis, and other clinical conditions.

    GMP Cytokines Market Report Coverage and Deliverables

    The “GMP Cytokines Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering the following areas:

    • GMP Cytokines Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Market dynamics such as drivers, restraints, and key opportunities
    • GMP Cytokines Market trends
    • Detailed PEST/Porter’s Five Forces and SWOT analysis
    • GMP Cytokines market analysis covering key market trends, Global and regional framework, major players, regulations, and recent market developments
    • GMP Cytokines Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
    • Detailed company profiles